Skip to content
OpenCapital
Get started
Income StatementBalance SheetCash FlowSegments
Neurocrine Biosciences logo

Neurocrine Biosciences Balance Sheet Statement

Assets, liabilities, and shareholders' equity

Neurocrine Biosciences holds $4.9B in total assets. Shareholders' equity is $3.4B against $463.5M in total debt. Cash and equivalents total $274.5M. The current ratio is 2.93 and debt-to-equity is 0.136. Based on the Q1 2026 filing.

Total Assets$4.9BTotal Stockholders Equity$3.4BCash And Equivalents$274.5MTotal Current Assets$2.4BTotal Current Liabilities$831.7M
Latest FilingQ1 2026
Report Date2026-05-05
Market Cap$16.4B
P/E Ratio24.47
ROE22.5%

Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Accounts payable$461.6M$475.2M$489.5M$584.3M$674.3M$773M
Accrued expenses$46.1M$57.5M$84.6M$105.1M$128.8M$81.7M
Accrued interest$14.4M$14.5M$16.7M$18.4M$20.5M$21.9M
Accrued liabilities and other current$109.9M$110M$104.6M$119.9M$104.9M$120M
Accrued Manufacturing Costs$107.5M$57.5M$84.6M$105.1M$128.8M$81.7M
Accounts payable and other current liabilities (Note 11)$461.6M$475.2M$489.5M$584.3M$674.3M$773M
Accrued Income Taxes, Current$9.9M$25.4M$25.7M—$68M$186.4M
Compensation and benefits$107.5M$57.5M$84.6M$105.1M$128.8M$81.7M
Other accrued liabilities$46.1M$47.7M$56.8M$53.7M$69.1M$58.7M
Income taxes payable$160.7M$25.4M$25.7M$195.5M$68M$186.4M
Lease Liability Payments - 2020 (Remaining Three Months)—$32.5M$23.1M$9.7M—$44M
Lease Liability Payments - 2021—$3.5M$3.5M$3.5M—$4M
Operating Lease Liability Payments - 2024 (Lessee)—$59.2M$59.2M$59.6M—$59.7M
Operating Lease Liability Payments - 2025 (Lessee)—$60.8M$60.8M$60.4M—$60.7M
Lease Liability Payments - Due Year Two—$59.2M$59.2M$59.6M—$59.7M
Lease Liability Payments - Due Year Three—$60.7M$60.7M$60.2M—$59.8M
Lease Liability Payments - Due Year Four—$60.8M$60.8M$60.4M—$60.7M
Lease Liability Payments - Remainder of Fiscal Year—$58.3M$58.3M$58M—$59.1M
Operating lease liabilities, current$40.6M$45.6M$50.7M$51.3M$56M$57.3M
Operating Lease Liability Payments Due—$645.9M$636.5M$619.5M—$590.2M
Operating Lease Liability - Undiscounted Excess Amount—$152.8M$146.7M$139.8M—$126.7M
Total current liabilities$507.7M$522.9M$546.3M$638M$743.4M$831.7M

Equity

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Additional paid-in capital$2.6B$2.5B$2.6B$2.7B$2.8B$2.8B
Accumulated other comprehensive income (loss)$5.8M$9M$12.5M$13.2M$13.1M$400K
Common stock100K220M220M220M220M220M
Common Stock Par Value Per Share$0.00$0.00$0.00$0.00$0.00$0.00
Common Stock Shares Issued99.4M99M99M99.7M100.1M100.6M
Convertible Preferred Stock Authorized Shares5M5M5M5M5M5M
Convertible Preferred Stock Issued Shares000000
Convertible Preferred Stock Outstanding Shares000000
Additional paid-in capital$2.6B$2.5B$2.6B$2.7B$2.8B$2.8B
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively$100K$100K$100K$100K$100K$100K
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding$0$0$0$0$0$0
Investments - Gross Unrealized Losses$458.7M$317.3M$401.8M$349.8M$335.1M$1.6B
Preferred stock$0$0$0$0$0$0
Preferred Stock Par Value Per Share$0.00$0.00$0.00$0.00$0.00$0.00
Retained earnings$29.2M-$5.3M$84.5M$294M$447.7M$589.6M
Total liabilities and stockholders' equity$3.7B$3.7B$3.9B$4.3B$4.6B$4.9B
Total stockholders' equity$2.6B$2.5B$2.7B$3B$3.3B$3.4B
Unrealized Losses on Investments (Before Tax)$1.7M$600K$500K$500K$600K$7.2M

Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
AFS and Trading Securities - Unrealized Loss Position Fair Value$458.7M$317.3M$401.8M$349.8M$335.1M$1.6B
Cash and cash equivalents$241M$202.1M$272M$348.2M$721M$274.5M
Cash, Cash Equivalents, and Marketable Securities$458.7M$317.3M$401.8M$349.8M$335.1M$1.6B
Available For Sale Securities Debt Securities Current$843.1M$749.4M$711.6M$774.6M$767.4M$1B
Other current assets$63.6M$119.3M$120.7M$68.2M$115.8M$62.5M
Income taxes receivable————$94M$127.7M
Finished goods$12.8M$13.6M$13.6M$16.2M$14.3M$12.9M
Raw materials$33.7M$31.9M$28M$40.1M$35.7M$30.7M
Work in process$10.9M$13.8M$15.5M$13.2M$19.2M$21.1M
Operating Lease Income - 2022 (Lessor)—$3.5M$3.5M$3.5M—$4M
Operating Lease Income - 2025 (Lessor)—$3.5M$3.5M$3.5M—$3.5M
Operating Lease Receivables (Current)—$22M$21.1M$20.2M—$20.1M
Other Inventory, Net$0$200K$200K$200K$200K$200K
Prepaid expenses and other current assets$48.5M$119.3M$120.7M$178.1M$21.1M$27.5M
Restricted cash—$8M$8M$8M—$8M
Short-term investments$843.1M$749.4M$711.6M$774.6M$767.4M$1B
Total current assets$1.7B$1.6B$1.7B$2.2B$2.5B$2.4B

Non-Current Assets

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Deferred tax assets$485.7M$499.4M$536.8M$368.5M$320.3M$381.4M
Deferred Tax Assets and Other Non-Current Assets$52M$15.3M$21.6M$20.3M$59.5M$73.6M
Available-for-sale securities$739.5M$815.3M$873.8M$998.5M$1.1B$1.3B
Equity securities$124.8M$94.2M$87.5M$118.1M$120.8M$146.1M
Net Investment in Lease$509.4M$22M$21.1M$20.2M$455.4M$20.1M
Long-term marketable securities$739.5M$815.3M$873.8M$998.5M$1.1B$1.3B
Deferred tax assets$485.7M$499.4M$536.8M$368.5M$320.3M$381.4M
Operating lease right-of-use assets$509.4M$502.2M$492.3M$468.9M$455.4M$447.1M
Other non-current assets$52M$15.3M$21.6M$20.3M$59.5M$73.6M
Operating Lease Income - 2026 (Lessor)—$3.5M$3.5M$3.5M—$4M
Operating Lease Income - 2027 (Lessor)—$3.5M$3.5M$3.5M—$3.6M
Operating Lease Income - 2028 (Lessor)—$3.5M$3.5M$3.5M—$3.5M
Operating lease right-of-use assets50940000000.0%4.9%4.9%4.9%45540000000.0%4.9%
Operating Lease Right-of-Use Assets in Other Assets$509.4M$502.2M$492.3M$468.9M$455.4M$447.1M
Other non-current assets$52M$22M$21.1M$20.2M$59.5M$20.1M
Property and equipment, net$82.6M$87M$91.7M$97.3M$89.8M$90.9M
Software and Technology Licenses, Net$52M$15.3M$21.6M$20.3M$59.5M$73.6M
Total assets$3.7B$3.7B$3.9B$4.3B$4.6B$4.9B

Non-Current Liabilities

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Operating Lease Liability Payments - 2026 (Lessee)—$60.7M$60.7M$60.2M—$59.8M
Operating Lease Liability Payments - 2027 (Lessee)—$60.7M$60.7M$60.2M—$59.8M
Operating Lease Liability Payments - 2028 (Lessee)—$60.8M$60.8M$60.4M—$60.7M
Operating lease liabilities, non-current$455.1M$447.5M$439.1M$428.4M$415.3M$406.2M
Operating Lease Liabilities (Total)$495.7M$493.1M$489.8M$479.7M$471.3M$463.5M
Other non-current liabilities$166.2M$181.6M$210.1M$195.7M$219.7M$260.9M
Total liabilities$1.1B$1.2B$1.2B$1.3B$1.4B$1.5B

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Operating Lease Income - 2023 (Lessor)—$3.5M$3.5M$3.5M—$3.6M
Operating Lease Income - 2024 (Lessor)—$3.5M$3.5M$3.5M—$3.6M
Current branded prescription drug fee$49.2M$38M$38M$39M$45.3M$42.9M
Income taxes payable – long-term$160.7M$166M$183M$195.5M$214.5M$241.3M
Accrued development costs$50.8M$89.7M$61M$82.4M$101.3M$110.7M
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax$1.7M$600K$500K$500K$600K$7.2M
Common stock, par value (in dollars per share)$0$0$0$0$0$0
Common stock, shares authorized (in shares)$220M$220M$220M$220M$220M$220M
Common stock, shares issued (in shares)$99.4M$99M$99M$99.7M$100.1M$100.6M
Common Stock, Shares, Outstanding$99.4M$99M$99M$99.7M$100.1M$100.6M
Debt Securities, Available-for-Sale, Unrealized Loss Position$458.7M$317.3M$401.8M$349.8M$335.1M$1.6B
Raw materials$33.7M$31.9M$28M$40.1M$35.7M$30.7M
Lessee Operating Lease Liability Payments Due—$645.9M$636.5M$619.5M—$590.2M
Thereafter—$374.4M$374.4M$371.6M—$306.9M
Lessee Operating Lease Liability Undiscounted Excess Amount—$152.8M$146.7M$139.8M—$126.7M
Lessor, Operating Lease, Payment to be Received, after Year Four—$5.4M$5.4M$5.3M—$2M
Remainder of fiscal 2026—$2.6M$1.7M$900K—$3M
Operating Lease Weighted Average Discount Rate Percent—$0$0$0—$0
Other noncurrent liabilities$5.5M$15.6M$27.1M$200K$5.2M$19.6M
Preferred Stock, Par or Stated Value Per Share$0$0$0$0$0$0
Preferred Stock, Shares Authorized$5M$5M$5M$5M$5M$5M
Preferred Stock, Shares Issued$0$0$0$0$0$0
Preferred Stock, Shares Outstanding$0$0$0$0$0$0
Prepaid development costs————$55.6M$69.6M
Prepaid expenses$48.5M——$178.1M$170.7M$224.8M
Provision for contract loss$144.2M$154.6M$175.6M$237.9M$226M$231.3M
Remainder of Fiscal Year 2024—$32.5M$23.1M$9.7M—$44M